Fenofibrate Tablets Generic Name & Formulations
Fenofibrate 54mg, 160mg.
Fenofibrate Tablets Indications
Adjunct to diet: in severe hypertriglyceridemia; and to reduce elevated total-C, LDL-C, ApoB, and TG, and to increase HDL-C in primary hyperlipidemia and mixed dyslipidemia.
Fenofibrate Tablets Dosage and Administration
Take with food. Hypertriglyceridemia: 54mg–160mg/day; adjust in 4–8 week intervals. Hypercholesterolemia, dyslipidemia: 160mg/day. Renal impairment (CrCl<50mL/min): initially 54mg/day. Discontinue if inadequate response after 2 months on max dose.
Fenofibrate Tablets Contraindications
Severe renal impairment. Dialysis. Active liver disease. Primary biliary cirrhosis. Unexplained persistent liver dysfunction. Gallbladder disease. Nursing mothers.
Fenofibrate Tablets Boxed Warnings
Fenofibrate Tablets Warnings/Precautions
Renal impairment. Monitor CBCs for first year; monitor liver function, discontinue if ALT (SGPT) levels >3xULN persist. Discontinue if markedly elevated CPK levels, myopathy, or gallstones occur. Pregnancy.
Fenofibrate Tablets Pharmacokinetics
Fenofibrate Tablets Interactions
Avoid statins. Potentiates oral anticoagulants (monitor). Allow at least 1 hour before or 4–6 hours after bile acid sequestrants. Caution with immunosuppressants (eg, cyclosporine), other nephrotoxic drugs.
Fenofibrate Tablets Adverse Reactions
Abnormal liver function tests, elevated CPK, respiratory or GI effects, myopathy, cholelithiasis, pancreatitis, increased creatinine, rash; rare: rhabdomyolysis, transient hematologic changes, blood dyscrasias.
Fenofibrate Tablets Clinical Trials
Fenofibrate Tablets Note
Formerly known under the brand name Lofibra.
Fenofibrate Tablets Patient Counseling